Ethnobridging: Clinical Research Capabilities

Ethnobridging in Phase I development demonstrates equivalence between Asian and non-Asian populations. Accomplished by comparing pharmacokinetics of the drug after administration to both ethnic groups, this strategy promotes a reduction in cost and development time, allowing sponsors to recruit patients in “global” safety and efficacy trials (Phase II-III) without repeating Phase I development in that region and population.

Altasciences recruits from a large ethnic population in Southern California and have a dedicated Asian recruitment and outreach department to liaise with our participants. With experience conducting over 190 ethnobridging studies since 2004, we offer two potential solutions:

• A single study once the target doses for the global study have been identified
• The addition of Asian subjects to the first-in-human (FIH) study

Altasciences delivers a fully integrated, seamless offering for your ethnobridging trials, with large and small molecule bioanalytical laboratories and comprehensive research support services.